MDT

Premium GrowerAI screen pass

Medtronic plc · Healthcare · Ireland · $122.0B cap · $1.8B/day traded

$100.72 -1.6% · close 18 Nov · scored 19 Nov

Premium Grower: Strong business with the market behind it, priced at a premium.

Full research report (Nov 2026), free
86
Score
Get score and insider alerts
Quality
63
Value
50
Momentum
74

As of 19 Nov 2026, the MoatMap Score for Medtronic plc (MDT) is 86/100, ranked against 25,000+ stocks in 38 markets (Quality 63, Value 50, Momentum 74, each scored against its sector).

Does the score work? Each tenth of the ranking, tracked monthly. See the record →

P/E (TTM)
25.3x
peers 23.2x
ROE
10.6%
peers 3.1%
D/E
0.6x
peers 0.2x
Dividend %
2.8%
trailing yield
AI screening note

Medtronic clears the calibrated bar. All three legs are above the floor (Q64 V57 M53) and an active buyback provides the required corroboration. Nothing adverse survives the evidence test: the only insider figure rounds to 0.00%, treated as unusable rather than adverse, and there is no negative earnings revision. Quality at Q64 is the strongest part of the case.

The ranks quoted here are from the day it was written; today's Quality, Value and Momentum are the bars above.

ABOUT MEDTRONIC PLC

Read

Medtronic plc is a global leader in medical technology, developing, manufacturing, and marketing a broad portfolio of medical devices and therapies for various chronic diseases, including cardiovascular, diabetes, and surgical solutions. The company maintains a strong competitive advantage through its extensive intellectual property, robust R&D pipeline, and deep clinical relationships, driving innovation in patient care worldwide.

FINANCIAL SUMMARY (USD)

Year20222023202420252026CAGRTTM2027E2028EFwd CAGR
Income and shares
Revenue—31.2B32.4B33.5B36.4B5.2%37.5B39.0B40.4B5.5%
Net margin—12.0%11.4%13.9%13.2%+1.2 pts————
EPS3.82.82.83.63.80.0%4.14.14.37.6%
Share count—1.3B1.3B1.3B1.3B-1.3%1.3B———
Balance sheet
Debt—24.4B25.0B28.5B28.0B4.7%28.2B———
Equity—51.5B50.2B48.0B49.5B-1.3%————
Debt/equity—0.5x0.5x0.6x0.6x+0.1x————
Cash flow
Op. cash flow—6.0B6.8B7.0B7.3B6.7%8.0B———
Cash flow margin—19.3%21.0%21.0%20.2%+0.9 pts21.4%———
Investing CF—-3.5B-2.4B-1.9B-2.9B—————
Financing CF—-5.0B-4.5B-4.4B-4.8B—————
PRICE (1Y) · USD+14.8%
87.892.196.41011058 Oct29 Oct18 Nov
SMA 50SMA 200

Price checkIn an uptrendExperimental

Above its 200-day average and 5% below its 52-week high.

SwingsCalm

Calmer than 82% of stocks we rank over the past year (volatility 26% a year).

How this is worked out

The Price check reads only the chart, the price side of the Momentum score in words; it is not the MoatMap Score.

  • Still falling: It set a new 52-week low in the last two weeks, after a deep fall.
  • Finding a floor: It fell hard, but has set no new low for more than two weeks.
  • Turning up: It has climbed off its low and is back above a rising 50-day average.
  • In an uptrend (this stock): It is near its 52-week high and above its 200-day average.
  • No clear trend: None of the above: no recent deep fall and no steady climb.
  • No read yet: Not enough price history yet: it needs a year of trading.

In past US falls, waiting for Turning up cut the chance of another 20% drop from 42% to 33%. Returns were no better, and 33% of turns failed.

The exact rules

Still falling is a new 52-week low in the last two weeks, at least 25% below the high, with the low set after the high. Finding a floor is the same fall with no new low in the last two weeks. Turning up is 20 or more trading days without a new low, at least 10% off it, and back above a rising 50-day average. In an uptrend is above the 200-day average, with the 50-day average above the 200-day, and within 15% of the high. No clear trend is everything else. No read yet is under 252 trading days of history, or missing data. A new state shows once it has held for three trading days.

In 2,112 US drawdowns since 2001, buying while the price was still falling was followed by a further 20% drop 42% of the time. Waiting for a turn (the Turning up rule above) cut that to 33%, at about 7% higher prices and with no better returns. Part of that cut is simply not buying: 13% of falls never turned, and waiting kept those out. Among turns that were bought, 38% still fell another 20%, and 33% of turns were followed by a new low within six months. The benefit was largest in crashes such as 2008 and 2020.

What it measures: how much the price moved day to day over the past year, scaled to a yearly figure (annualised volatility) and ranked against every stock we cover. Very calm under 20% a year, Calm 20 to 30%, Average 30 to 40%, Bumpy 40 to 55%, Very bumpy above that.

What we found: across about 13,500 stocks in 34 markets (2002 to 2025), past swings were a good guide to the next year's, and bumpier stocks fell further. How much further changed too much between eras to put a number on it.

Calm is not safe: a calm stock can still slide steadily.

Rules fixed before any data was fetched. Describes the chart, not a recommendation.

Close
$100.72
RSI (14)
59.1
52-Week Range-5.2% from high
Low $72.06High $106.20

SCORE BREAKDOWN

Quality
63
ROIC
8.4%64.0
ROE
10.6%71.0
GP/Assets
26.3%57.9
Op. Margin
20.1%84.1
FCF/Assets
5.8%72.1
Piotroski
784.1
Int. Cover
9.6x61.3
D/E Ratio
0.55x26.6
Current Ratio
2.07x41.0
Value
50
P/E (TTM)
25.3x46.6
EV/EBITDA
14.6x47.4
P/FCF
22.5x48.7
P/B
2.6x46.6
P/S
3.5x49.0
Div Yield
2.8%67.2
Momentum
74
52W High %
95%92.7
RS 6M
32%85.4
SMA 50/200
1.08x77.9
EPS Rev 4W
0.0%46.7
EPS Rev 12W
-0.1%48.6
EPS Improve
+57%60.3
Q Growth
41%71.5

FUNDAMENTALS

Market Cap
$122.0B
P/E (Forward)
16.1x
Gross Margin
65.3%

SECTOR PEERS

Closest peers in Healthcare, ranked by industry match, size, and score similarity. Cross-listings of MDT are excluded.

TickerCompanyMkt CapScore
MDTMedtronic plc(you)$122.0B86
SHL.DESiemens Healthineers AG$52.5B87
EWEdwards Lifesciences Corporation$51.3B77
SYKStryker Corporation$117.8B58
GEHCGE HealthCare Technologies Inc.$32.3B83
DXCMDexCom, Inc.$29.4B84
ABTAbbott Laboratories$179.4B63
PHGKoninklijke Philips N.V.$26.3B84
300760.SZShenzhen Mindray Bio-Medical Electronics Co., Ltd.$32.2B77
STESTERIS plc$22.6B84

Peer medians: ROE 3.1% · P/E 23.2x · Gross margin 53.1%

Company Deep Dive

Read the full report: the business and its segments, what management promised on earnings calls and whether it delivered, the competition, and how things could turn out.

View Deep Dive

Medtronic plc (MDT): Stock Score Summary

Medtronic plc (MDT) has a MoatMap Score of 86/100 based on Quality (63/100), Value (50/100), and Momentum (74/100) factor scores. Medtronic clears the calibrated bar. All three legs are above the floor (Q64 V57 M53) and an active buyback provides the required corroboration. Nothing adverse survives the evidence test: the only insider figure rounds to 0.00%, treated as unusable rather than adverse, and there is no negative earnings revision. Quality at Q64 is the strongest part of the case.

Medtronic plc is a global leader in medical technology, developing, manufacturing, and marketing a broad portfolio of medical devices and therapies for various chronic diseases, including cardiovascular, diabetes, and surgical solutions. The company maintains a strong competitive advantage through its extensive intellectual property, robust R&D pipeline, and deep clinical relationships, driving innovation in patient care worldwide.

Director dealings

From 2 Jan 2026 to 19 Nov 2026, MoatMap's records hold 6 sales and no purchases of Medtronic plc (MDT) shares by its directors. The largest: KIIL HARRY SKIP sold 52,524 shares at $97.71 on 19 Feb 2026 (about $5.1M).

  • 15 Oct 2026: Marinaro Michael sold 10,420 shares at $96.00 (about $1.0M)
  • 15 Oct 2026: Martha Geoffrey sold 50,000 shares at $95.00 (about $4.8M)
  • 16 Sep 2026: KIIL HARRY SKIP sold 1,483 shares at $93.65 (about $139K)
  • 8 Jul 2026: Walter Matthew R. sold 3,102 shares at $83.15 (about $258K)
  • 8 Jun 2026: KIIL HARRY SKIP sold 4,189 shares at $80.44 (about $337K)
MDT insider filings, last 180 days

Key Financial Metrics

Price$100.72
Market Cap$122.0B
P/E (TTM)25.27
P/E (Forward)16.06
Price/Book2.62
Return on Equity10.6%
Return on Invested Capital8.4%
Debt/Equity0.55x
Gross Margin65.3%
Operating Margin20.1%
Revenue Growth13.7%
Dividend Yield2.8%
Free Cash Flow$5.4B

Medtronic plc operates in the Medical Devices industry, part of the Healthcare sector (Ireland).

Frequently Asked Questions

What is Medtronic plc’s (MDT) MoatMap Score?
The MoatMap Score for Medtronic plc (MDT) is 86/100. It is a composite of Quality (63), Value (50), and Momentum (74), each scored against its sector. The composite is then ranked across MoatMap’s universe of 25,000+ stocks.
Does Medtronic plc have an economic moat?
Medtronic plc (MDT) has a Quality factor score of 63/100. Quality blends several measures of profitability and financial strength, led by gross profit to assets, return on invested capital and free cash flow to assets. A high score describes the financial record a durable advantage tends to leave; it does not prove a moat.
What sector is Medtronic plc in?
Medtronic plc (MDT) operates in the Healthcare sector, specifically the Medical Devices industry (Ireland).